Clinical Research Directory
Browse clinical research sites, groups, and studies.
Two Schemes Response in Multiple Myeloma
Sponsor: Hospital General de Mexico
Summary
Retrospective study based on medical records of patients with multiple myeloma, eligible for stem cell transplantation, who received, first-line, the VTD or TD combination.
Official title: Bortezomib, Thalidomide, and Dexamethasone Versus Thalidomide and Dexamethasone for Response Rates in Multiple Myeloma Patients: a Retrospective Study
Key Details
Gender
All
Age Range
18 Years - 90 Years
Study Type
OBSERVATIONAL
Enrollment
83
Start Date
2023-11-20
Completion Date
2024-10-30
Last Updated
2024-10-02
Healthy Volunteers
No
Conditions
Interventions
Bortezomib
Bortezomib 1.3mg/m2 SC on days 1,4, 8,11 to the TD scheme for a total of 6 treatment cycles (14,15) (VTD)
Locations (1)
Hospital General de Mexico Dr. Eduardo Liceaga
Mexico City, Mexico City, Mexico